

Targeted Therapies™

11.2023 | VOL. 12 NO. 16

IN ONCOLOGY

Regulatory Roundup Page 14

BXCL701 and Pembrolizumab Combo Yields OS Improvements in SCNC Page 45

Guideline Spotlights Early-Line Agents for GEP-NETS Page 48

Promising ADCs Emerge

in Non-Small Cell Lung Cancer

PAGE 18

final art tk

TP53-Mutated MCL Responds to Immunotherapy Combo

IN THIS ISSUE'S *Precision Medicine in Oncology* article, patients with TP53-wild-type mantle cell lymphoma deliver an overall response rate of 88% (n = 43), all with a complete response, after a median follow-up of 63 months (range, 11-84). Patients received immunochemotherapy with lenalidomide (Revlimid), according to investigators. **p43**

RMC-6236 Shows Safety, Efficacy in KRAS G12X Tumors

FINDINGS FROM A PHASE 1 trial (NCT05379985) evaluating RMC-6236 for dosage, safety, and efficacy were positive in patients with solid tumors harboring KRAS G12X mutations across various cancer types. Investigators delivered results during the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference. **p22**

Epcoritamab Shows Antitumor Activity in R/R CLL

SINGLE-AGENT EPCORITAMAB-BYSP (Epkiny) demonstrated promising antitumor activity in high-risk patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in the expansion cohort of the phase 1b/2 EPCORE CLL-1 trial (NCT04623541). Findings were presented during the 2023 International Workshop on CLL. **p34**

Peers & Perspectives® in Oncology

For further insight on managing oncology-based patient cases, view TargetedOnc.com/link/2291

